LIVA-HEALTHCARE
13.5.2020 09:32:04 CEST | Business Wire | Press release
Liva Healthcare continues its UK growth plan with four new contracts as part of the Healthier You: NHS Diabetes Prevention Programme (NHS DPP). The NHS DPP is delivered by a group of providers including Liva and Living Well Taking Control (LWTC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005029/en/
This follows Liva's announcement of 13 contract wins across healthcare providers, insurance and pharmaceutical organisations at the start of 2020. The company also secured an investment of €8 million from three venture funds in 2019.
The four clinical commissioning groups (CCGs) that will now have access to Liva’s diabetes prevention programme are; Derbyshire, Nottinghamshire, Northamptonshire, and Worcester and Hereford. CCGs in Dorset, Shropshire, Wrekin, and Telford have already been welcomed onto the programme.
Over the next three years, as part of the Healthier You: NHS Diabetes Prevention Programme, Liva will deliver personal health coaching to almost 11,000 patients who are at high risk of Type 2 diabetes. This is in addition to nearly 44,000 patients who will have access to Liva's app to supplement a face-to-face intervention programme led by LWTC.
Liva Healthcare is a Copenhagen and London based health tech company that provides patients with access to a dedicated health coach for professional guidance, support, and empathy. Regular coaching sessions help patients tackle chronic conditions through sustainable lifestyle and behaviour changes. The Liva programme has been proven to halt and reverse the progression of Type 2 diabetes.
Kristoffer From, CEO at Liva Healthcare, says: " This is an exciting achievement and demonstrates our commitment to the UK healthcare industry. Taking on these contracts proves how adaptable and scalable our proposition is. We are proud to be a partner to the Healthier You: NHS Diabetes Prevention Programme.
"The NHS is leading the charge in the global fight against diabetes. This programme is the largest of its kind and by incorporating digital and face-to-face interventions, the NHS is demonstrating its commitment to healthcare innovation.
“It is important that patients at high risk of developing Type 2 diabetes can access support beyond traditional in-person services. Anybody going through our programme will receive professional guidance, support, and empathy, to help tackle or prevent chronic conditions through sustainable lifestyle and behavior changes."
Liva will continue to invest in its established markets across Europe, Asia-Pacific and Canada while it expands into key European growth markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005029/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenAI and Yubico Partner to Bring Custom Phishing-Resistant YubiKeys to OpenAI Users30.4.2026 19:13:00 CEST | Press release
New strategic, long-term partnership with OpenAI delivers the gold standard of hardware-backed passkeys to the AI ecosystem Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the YubiKey, the gold standard of security keys, today announced an industry-first collaboration with OpenAI, the creator of ChatGPT. Beginning today, people can purchase a new 2-pack set of custom YubiKeys as part of OpenAI’s Advanced Account Security program – enabling them to secure their ChatGPT accounts with security keys, containing the strongest hardware-backed passkeys. Specifically designed for security-conscious users who are at increased risk of targeted digital attacks, the set includes a YubiKey C NFC for tap-to-authenticate on mobile, and a low profile YubiKey C Nano that stays in a port for everyday laptop use – both packed with modern authentication features for the highest level of protection. With OpenAI already using YubiKeys internally to protect
rhode Continues Its Global Retail Expansion Into Sephora Europe30.4.2026 18:00:00 CEST | Press release
This expansion into Sephora Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand rhode, the beauty brand founded by Hailey Rhode Bieber, will be available at Sephora online and in most stores across Europe beginning this September, following its 2025 rollout with Sephora in the U.S., Canada, and the U.K. This expansion into Sephora Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430569580/en/ rhode continues its global retail expansion into Sephora Europe. rhode’s collection of high-performance, skin-focused products saw strong performance in Sephora U.S. and Canada as the biggest brand launch in the retailer’s history in North America. When launched in November 2025 in the U.K., rhode was also the largest brand launch in Sephora U.K.’s history. “I’m so excited
ABS Acquires RMC Global to Strengthen Cyber, Risk and Resilience Capabilities30.4.2026 17:46:00 CEST | Press release
Acquisition to Deliver Stronger, More Integrated Solutions for Clients ABS, through its affiliate ABSG Consulting Inc. (ABS Consulting), has today announced the acquisition of RMC Global (RMC), a leading provider of industrial cybersecurity, risk management and resiliency solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430164690/en/ (L to R): Vince Kuchar, President, RMC Global, and David Wechsler, President and CEO, ABS Group The acquisition strengthens ABS Consulting’s capabilities and market position, bringing together two organizations with complementary expertise, shared values and a common mission. Combining RMC’s capabilities with ABS Consulting’s scale, technical depth and global resources, unlocks more integrated solutions for clients operating in increasingly complex risk environments. ABS Chairman and CEO John McDonald said: “Clients are facing increasing operational risk, cyber threats, and regulator
Brightfin Unveils AI-Native Platform for IT Financial Management30.4.2026 17:00:00 CEST | Press release
Brightfin clients drive their businesses forward with the first AI Native Cost Optimization Platform Brightfin, the only ITFM and Technology Expense Management solution built natively on ServiceNow, today announced an AI-Native architecture that fundamentally improves how organizations manage IT spend. Rather than bolting AI onto legacy systems, Brightfin has engineered intelligence from the ground up - starting with the data, building contextual awareness on top of it, and delivering AI agents that speak the language of IT finance. Brightfin’s unified budget-to-billing data model creates a stable, governed foundation that connects contracts, invoices, inventory, and budgets into a single source of truth - something no external ITFM tool or native platform module can replicate. This is a structured financial backbone purpose-built for enterprise IT spend, and it’s what makes everything above it possible. A context-aware, AI-Native, intelligence layer understands relationships across th
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 15:22:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom